Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 13 October 2009, doi:10.1136/bmj.b4201
Cite this as: BMJ 2009;339:b4201
Paul Benkimoun
1 Paris
| The first 150 words of the full text of this article appear below. |
Frances antidoping agency has uncovered "a surprising therapeutic arsenal," including two drugs that are not yet licensed, after scrutinising bins in the wake of the 2009 Tour de France.
Michel Rieu, the scientific adviser of the French Agency Against Doping (Agence Française de Lutte Contre le Dopage), said at a press conference on 7 October, "These are incongruous products in a milieu where people are supposed to be in good health."
Professor Rieu said that this "surprising therapeutic arsenal" had been reported to the World Anti-Doping Agency in July.
The agency said it suspected that some cyclists were using blood transfusions and two unlicensed substances.
Pierre Bordry, head of the agency, told the French daily Le Monde on 28 July that he was "convinced that two new products have been used during the [2009] tour, two drugs that are not yet on the market."
The first is a "third generation"
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?